Immumem Therapeutics Email Formats
Biotechnology Research • 
2930 Domingo Ave, 1568, United States • 1-10 Employees
Key Contact at Immumem Therapeutics
Najeebah Abdul-Musawir
Senior Medical Director & Scientific Advisor, Oncology
Company overview
| Headquarters | 2930 Domingo Ave, 1568, Berkeley, California 94705, US |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Oncology, Immunotherapy, Cell Therapy |
| Founded | 2024 |
| Employees | 1-10 |
About Immumem Therapeutics
Immumem Therapeutics engages in development of scalable and affordable allogeneic iPSC-derived cell therapies using a novel immunological memory platform against lethal cancer types such as pancreatic, colorectal, ovarian, and cervical cancer.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Director
Funding Data
Immumem Therapeutics has never raised funding before.
New Zealand
United Kingdom
Norway
France
AustraliaFrequently asked questions
Immumem Therapeutics is located in 2930 Domingo Ave, 1568, US.
Immumem Therapeutics was founded in 2024, making it 2 years old. The company has established itself as a significant player in its industry over this time.
Immumem Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
